Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Innovative Industrial Properties

Marijuana Stocks To Watch For Long Term Investing The post Should You Go Long On These Top Marijuana Stocks To Buy? appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

Should You Go Long On These Top Marijuana Stocks To Buy?

NORTH CHICAGO, Ill., May 19, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present results from 43 abstracts across 12 types of cancer during the upcoming virtual American Society of Clinical Oncology (ASCO) Annual Meeting (June 4-8) and the virtual European Hematology Association (EHA) congress (June 9-17).

AbbVie to Showcase Breadth of Oncology Portfolio and Pipeline at the 2021 ASCO and EHA Annual Congresses

AbbVie Inc. (ABBV) Presents at 2021 RBC Capital Markets Global Healthcare Conference (Transcript)

AbbVie Inc (NYSE: ABBV) significantly inflated prices over the past two decades for patients in the U.S. who take the drugs Humira and Imbruvica, a report released by the House Oversight and Reform Committee found. The committee concluded that the price increases led to billions of dollars in corporate revenue and hefty bonuses for company executives.

AbbVie Inflated Prices For Two Major Drugs, Engaged In Anticompetitive Practices, House Oversight Report Says

AbbVie Inc.'s pricing practices for some of its top-selling medicines faced fresh scrutiny from federal lawmakers Tuesday, the latest effort by members of Congress probing the cost of prescription drugs.

The Wall Street Journal: House Committee takes on AbbVie's pricing, patents for top-selling drug Humira

In recent earnings results, it stood out among its peers.

After a Blowout Quarter, Is AbbVie Stock a Buy?

Speculative manias are all around us, from Dogecoin recently surpassing $100 billion in market cap to the S&P 500 becoming 38% overvalued. Fortunately, wonderful blue-chip bargains are always available, if you know where to look.

3 Reasons AbbVie Is One Of The Best Buffett Blue-Chip Bargains On Wall Street

Chevron

Kimberly-Clark

Income investors will find plenty to like about these reliable and generous dividend payers.

3 Dividend Stocks That Pay You Better Than Coca-Cola Does

Pressure is rising on AbbVie as the $203 billion pharmaceutical company faces congressional scrutiny and a new legal battle over the core of its business. The Icelandic generic-drug specialist Alvotech launched a legal battle this week against AbbVie, challenging the patents that protect its best-selling medicine, Humira. Alvotech's goal is to launch a copycat version of Humira that would be sold at a cheaper price, known as a biosimilar.

AbbVie faces the biggest challenge yet to its best-selling medicine, Humira, as an unlikely Icelandic drugmaker launches a legal fight over 'outrageous' patents

Kraft Heinz

ViacomCBS

Not only do they offer higher yields, but they could also generate great returns this year as their businesses continue to grow.

Forget Walmart, Here Are 3 Better Dividend Stocks

Soliton

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Soliton, Inc. (NasdaqGS: SOLY) to AbbVie, Inc. (NYSE: ABBV). Under the terms of the proposed transaction, shareholders of Soliton will receive only $22.60 in cash for each share of Soliton that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whet

SOLITON INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Soliton, Inc. - SOLY

NORTH CHICAGO, Ill., May 12, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the RBC Capital Markets Global Healthcare Conference on Tuesday, May 18, 2021.

AbbVie to Present at the RBC Capital Markets Global Healthcare Conference

NextEra Energy

PepsiCo

Let's dive into three strong dividend-paying stocks that could be solid long-term holds.

3 Strong Dividend Stocks to Buy for Market Volatility and Inflation Fears

AbbVie Enters Growing Market for Tattoo Removal, Cellulite Treatment

NEW YORK, May 10, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Soliton, Inc. ("Soliton" or the "Company") (NASDAQ: SOLY) in connection with the proposed acquisition of the Company by Allergan Aesthetics, an AbbVie company (NYSE: ABBV). Under the terms of the merger agreement, Allergan Aesthetics will pay Soliton shareholders $22.60 in cash for each Soliton share that they own.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Soliton, Inc.

AbbVie Inc (NYSE: ABBV) is making an opportunistic play to boost the aesthetics business by adding a long-delayed body sculpting product into the fold. AbbVie's Allergan Aesthetics unit will pay $550 million in cash to scoop up Soliton Inc (NASDAQ: SOLY) and Resonic, its sound-wave device that improves the appearance of cellulite.

Soliton Stock Rallies After $22.60/Share Buyout From AbbVie

IRVINE, Calif. and HOUSTON, May 10, 2021 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) and Soliton (NASDAQ: SOLY) today announced a definitive agreement under which Allergan Aesthetics will acquire Soliton and RESONICTM, its Rapid Acoustic Pulse device which recently received U.S. Food and Drug Administration (FDA) 510(k) clearance and is a non-invasive treatment for the short-term improvement in the appearance of cellulite.

Allergan Aesthetics to Acquire Soliton, Expanding Body Contouring Portfolio

Aflac

Becton, Dickinson and Co.

Cardinal Health

Cincinnati Financial

ProShares S&P 500 Dividend Aristocrats ETF

Realty Income Corp

People's United Financial

AT&T

Dividend Aristocrats can be a great choice for investors looking for reliable income and stocks that can outperform during a recession. Not all Dividend Aristocrats are necessarily attractive at the same time, however.

10 Of The Best Value Picks Among Dividend Aristocrats

It might not be too late to pick up shares of the big pharma company.

Is It Too Late to Buy AbbVie Stock in 2021?

Marsh & McLennan

Merck

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Bristol-Myers

GuruFocus runs a contest every quarter in which people guess the stocks they think Warren Buffett (Trades, Portfolio) might have bought.

Guess Which Stocks Warren Buffett Bought: 1st-Quarter Contest

Amazon

American Express

Charter Communications

VeriSign

As one of the world's greatest investors, Warren Buffett knows a thing or two about acquiring the best stocks to buy. The post 7 Warren Buffett Stocks to Buy for the Next Decade appeared first on InvestorPlace.

7 Warren Buffett Stocks to Buy for the Next Decade

Is AbbVie stock a buy now that shares are recovering somewhat after the Food and Drug Administration requested additional data before considering new approvals for Rinvoq? The post AbbVie Stock Is Tackling Its New Buy Point — Is It A Buy Right Now?

AbbVie Stock Is Tackling Its New Buy Point — Is It A Buy Right Now?

Zynga

Earlier this week, investment firm Diamond Hill Capital (Trades, Portfolio) disclosed its portfolio for the first quarter, which ended March 31.

Diamond Hill Capital Reveals Top 1st-Quarter Trades

Enbridge

Manulife Financial

Philip Morris

Prudential Financial

ESG investing has become red hot in recent years, and $20 trillion of assets are expected to flow into ESG funds in the next two decades. Some think ESG is the newest alpha factor. Thus far studies show it's merely an indicator of overall fundamental risk and quality, similar to credit ratings.

5 High-Yield ESG Blue-Chips For A Safe And Prosperous Retirement

AbbVie (ABBV) closed at $113.98 in the latest trading session, marking a -0.61% move from the prior day.

News for AbbVie Stock (ABBV)